ClinicalTrials.gg
RecruitingNCT07030166Updated Apr 2, 2026

A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients

An observational study in Kidney Injury, Acute, sponsored by Lanyue Zhu. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Lanyue Zhu · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Planned enrollment
13th of 105
10,000 · median 472
Started
2025
with 9 others
Observational
105 of 168
26 open now
Primary completion
2026-12
later than 21 of 53 live
Registered
133rd of 168
by date

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 13th largest by planned enrollment of the 105 observational ones that give a count, is one of 10 that started in 2025, is one of 105 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 133rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

Primary objectives of this study is to develop and validate a predictive model for acute kidney injury after non-cardiac surgery based on machine learning. Secondary objectives of this study is to incorporate frailty assessment as a new predictor into the model and measure its incremental value was measured.

Read the detailed description

The data in this study are divided into two parts: retrospective and prospective. The retrospective data served as the development set, sourced from the electronic medical records of adult patients who underwent non-cardiac surgery during hospitalization between July 2015 and June 2025. The prospective data constituted an external (temporal) validation set, with data collection commencing in July 2025 and expected to conclude in February 2026.

03

Conditions studied

  • Kidney Injury, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are scheduled to undergo surgery at Zhongda Hospital Southeast University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or above
  • Undergo non-cardiac surgery

Exclusion criteria

Exclusion Criteria:

  • At least one measurement of serum creatinine (SCr) was not conducted before and after the operation
  • End-stage renal disease (ESRD) that has received dialysis within the past year
  • Baseline SCr ≥ 4.5 mg/dl (because the clinical criteria for AKI based on elevated SCr may not be applicable to these patients)
  • Acute kidney injury occurred within 7 days before the operation
  • The surgical procedure is renal surgery
  • The operation time is less than 2 hours
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Development group

    The development group was used for model development, five-fold cross-validation, and model optimization. The investigators collected a comprehensive set of variables for feature selection, including preoperative demographic characteristics (sex, age, body mass index, marital status, occupation, etc.), laboratory indicators (routine blood and urine tests, liver and kidney function, coagulation function, etc.), preoperative comorbidities, and surgical information (surgical department, surgical classification, American Society of Anesthesiologists physical status classification, intraoperative position, fluid intake and output, vital signs, intraoperative medication use, etc.). Subsequently, multiple machine learning methods, including logistic regression, extreme gradient boosting, decision tree, random forest, and Bayesian approaches, were employed for model building and optimization.

    Other: No intervention measures were used.

  • External (time) validation group

    The external (time) validation group is used for future generalization ability assessment. The investigators prospectively collected patient-related data. In addition to the same variables as those in the development group and the testing group, the investigators also evaluated and collected the frailty status of patients before the operation, and recorded prognostic indicators such as the incidence of in-hospital complications, in-hospital mortality, length of hospital stay and hospitalization cost of patients. The investigators used the data from the external (time) validation group to validate the model performance, incorporated the frailty assessment as a new predictor into the model, calculated the incremental values and evaluated the performance of the updated model.

    Other: No intervention measures were used.

Interventions

  • OtherNo intervention measures were used.

    The exposure factors were the perioperative related operations experienced by the patients and their individual conditions

06

What researchers measure

Primary outcomes

  1. Acute kidney injury

    Time frame: Within 7 days after the operation

Secondary outcomes

  1. Postoperative complications

    Time frame: Perioperative period

  2. Postoperative mortality

    Time frame: Perioperative period

  3. Hospitalization costs

    Time frame: Perioperative period

  4. Hospital stays

    Time frame: Perioperative period

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 17 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2025
First posted
Jun 22, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07030166
Lead sponsor
Lanyue Zhu
Responsible party
Lanyue Zhu (Attending Physician, Zhongda Hospital) — Sponsor-investigator
First posted
Jun 22, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Yue Lan Zhu
Contact
zhulanyue1993@126.com
+8618795969178

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion